Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.

ABSTRACT:

Objective

To investigate the origin of the HIV-1 viremia induced by the latency-reversing agent romidepsin.

Design

Six individuals on suppressive antiretroviral therapy received romidepsin administered intravenously once weekly for 3 consecutive weeks. CD4 T cells were obtained at baseline, following the second and third romidepsin infusion, and 10 weeks after the final romidepsin treatment. Plasma samples were collected 24 and 72 h after romidepsin infusions.

Methods

Single-genome sequencing of the env and p24-RT region was used to genetically characterize the virus from proviral DNA, the transcribed cell-associated RNA and the plasma RNA pool.

Results

In three of six participants with available plasma samples we identified plasma HIV-1 RNA sequences that were

SUBMITTER: Winckelmann A 

PROVIDER: S-EPMC5345886 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature